View Older Stories View More Recent Stories
-
Humana earnings preview Q1: softer profit expected amid Medicare costs
-
Evercore ISI on Humana (HUM): CenterWell partnership with Cuban Cost Plus offers 'some modest benefit'
-
CenterWell Pharmacy partners with Mark Cuban Cost Plus Drug Company
-
Wolfe Research sees managed care companies underearning targets by up to 400%
-
UnitedHealth Group (UNH) Reiterated at Overweight by Cantor Fitzgerald Amid Trough Margins
-
Humana (HUM) PT Lowered to $258 at Mizuho
-
Humana (HUM) Reiterated at Neutral by Cantor Fitzgerald Amid Margin Concerns
-
Humana (HUM) call put ratio 1 call to 1.6 puts into health insurers Medicare rate hike
-
Humana shares surge 12% on 2027 Medicare rate boost; UNH, CVS Rally
-
Humana (HUM), UnitedHealth Group (UNH) Spike: Medicare Finalizes 2.48% Rate Hike For Private Insurers In 2027
-
These 12 stocks have the highest activist attractiveness scores
-
Humana (HUM) PT Lowered to $211 at Bernstein; '2026 guidance is much lower than we expected'
-
Humana (HUM) PT Lowered to $211 at Bernstein SocGen Group
-
Humana (HUM) PT Lowered to $182 at Piper Sandler
-
Humana completes $1 billion junior subordinated notes offering
-
Humana reaffirms 2026 earnings guidance ahead of investor meetings
-
UBS Reiterates Neutral Rating on Humana (HUM)
-
Humana (HUM) PT Lowered to $176 at Barclays
-
Humana commits $1.7 million for Illinois health programs
-
Humana (HUM) PT Lowered to $201 at Cantor Fitzgerald as Stock to Be Range-Bound till Q2
-
RBC Capital Downgrades Humana (HUM) to Sector Perform
-
Humana (HUM) PT Lowered to $252 at Guggenheim
-
Humana (HUM) PT Lowered to $180 at Evercore ISI
-
Humana shares fall as 2026 earnings guidance disappoints investors
-
Humana (HUM) Tops Q4 EPS by 4c, Beats on Revenue; Offers FY26 EPS Guidance
-
Humana Q4 Preview
-
Humana (HUM) call put ratio 1.1 calls to 1 put into expected release of quarter results on February 12
-
Humana (HUM) call put ratio 1 call to 1.7 puts into quarter results
-
Guggenheim Reiterates Buy Rating on Humana (HUM)
-
Morgan Stanley Downgrades Humana (HUM) to Underweight
-
Health insurers slide after 2027 Medicare Advantage payments proposal underwhelms
-
Piper Sandler: 'We Would Be Buyers of ALHC, CVS on Selloff, UNH Post-EPS'
-
Humana (HUM) call put ratio 1 call to 1.5 puts
-
After-hours movers: Humana, UnitedHealth, CVS Health, Sanmina and more
-
Trump Administration Proposes Flat Rates for Medicare Advantage, CMS and White House Say -- WSJ
-
Humana (HUM) PT Lowered to $310 at Jefferies
-
Humana partners with Atlas Oncology for Medicare cancer care in two states
-
Humana (HUM) call put ratio 1 call to 1.1 puts
-
Cigna Corp. (CI) And Others Watch Amid Circulating Online Research Report
-
UnitedHealth, Humana, Cigna fall after Trump comments on insurance pricing
-
Trump: Insurance Companies Need to Get Their Prices Down
-
Humana announces leadership changes as insurance chief plans retirement
-
BofA Comments on GLP-1s and Potential Pressure Ahead
-
KeyBanc Reiterates Sector Weight Rating on Humana (HUM)
-
Humana (HUM) May Have Limited Near-term Upside - Cantor Fitzgerald
-
Jefferies Upgrades Humana (HUM) to Buy
-
Mark Cuban in talks with Humana on pharmacy partnership
-
Humana reaffirms 2025 earnings guidance ahead of investor meetings
-
Plus Therapeutics secures Humana coverage for brain cancer test
-
Humana (HUM) PT Lowered to $310 at Mizuho
